Thursday turned into a costly affair for Danish pharmaceutical company Lundbeck.
The European Court of Justice has turned down Lundbeck's appeal and established that Lundbeck has violated EU competition law, for which reason it has to pay a EUR 93.7m (USD 110.6m) fine, according to an announcement from the EU Court of Justice.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.